

Index

Note: Page numbers of article titles are in **boldface** type.

- Abortion, spontaneous, mycoplasmas in, 506
Acquired immunodeficiency syndrome. See *Human immunodeficiency virus infection*.
- Acridine orange stain, in vaginal trichomoniasis, 527-528
- Agar dilution method, in *Neisseria gonorrhoea* susceptibility testing, 463
- AIDS. See *Human immunodeficiency virus infection*.
- Anaerobic vaginosis, 528-532
- Anergy, in HIV infection, 395
- Antibiograms, in *Neisseria gonorrhoea* susceptibility testing, 467
- Antibiotic susceptibility testing, in chlamydial infections, 493-494
in gonorrhea, 460-470
- Antibody tests, in genital herpes infection, 412-416
in HIV infection. See under *Human immunodeficiency virus infection*.
- Antigen detection tests, in mycoplasma infections, 514
- Arthritis, mycoplasmas in, 507-508
- Auxotype/serovar classification, in *Neisseria gonorrhoeae* phenotyping, 470
- Auxotyping, in *Neisseria gonorrhoeae* susceptibility testing, 467
- Bacterial vaginosis, 528-532
- Bacteriodes*, in vaginosis, 529-530
- Beta-lactamase detection, in *Neisseria gonorrhoeae* susceptibility testing, 465
- Beta₂-microglobulin, in HIV infection, 395, 398
- Biohazardous (infectious) waste, 579-582
- Bowenoid papulosis, 425, 427
- Branhamella catarrhalis*, identification of, 454
- Bushke-Lowenstein tumor, 424, 426-427
- Campylobacter granulomatis*, in granuloma inguinale, 540-541
- Cancer, papillomavirus and, 423
- Candida albicans*, in vaginitis, 525-526, 563
- Card tests, in syphilis, 550-551
- CBre3 env ELISA test, in HIV infection diagnosis, 376
- CD4 assay, in HIV infection, 381-382, 394-395, 397
- CD8 assay, in HIV infection, 397
- Cell culture, in chlamydial infections, 490-493
- Cephalosporins, in gonorrhea, 460-461
- Cervix, papillomavirus infection of, 427-429
neoplasia and, 423
- Chancroid, 535-540
causative organism of, 535-536
clinical features of, 539
epidemiology of, 536-538
laboratory diagnosis of, 538-539
natural history of, 539-540
prevention of, 540
treatment of, 539-540
- Chemical waste management, 575-578
- Chemilluminescence test, in gonorrhea, 458
- Chlamydia trachomatis*, antibiotic susceptibility testing of, 493-494
biology of, 483-484
elementary body of, 483-484, 488
laboratory tests for, antigen detection, 487-490
cell culture, 490-493
cytologic, 563-565
direct examination, 486
specimen collection for, 484-486
reticulate body of, 483-484
serologic testing of, 494

- Chlamydial infections, genital, 481-500
 antibiotic susceptibility testing in, 493-494
 antigen detection in, 487-490
 asymptomatic, 481-482
 causative organism characteristics in, 483-484
 cell culture isolation in, 490-493
 cytologic tests in, 563-565
 direct fluorescent monoclonal antibody staining in, 487-489
 direct specimen examination in, 486
 DNA hybridization assay in, 489-490
 enzyme immunoassay in, 489
 incidence of, 481
 serologic testing in, 494
 serotyping in, 483
 specimen collection in, 484-486
- Chlamydiae test, in chlamydial infections, 489
- Chorioamnionitis, mycoplasmas in, 506
- Chromatography, in vaginosis diagnosis, 530
- Clue cells, in *Gardnerella vaginalis* vaginitis, 561
- Coagglutination tests, in gonorrhea, 457
- Complement fixation, in mycoplasma infections, 516
- Condyloma acuminatum. See *Papillomavirus infections, genital*.
- Cytologic tests. See also *Pap smear*.
 in papillomavirus infections, 426
- Cytopathic effect test, in genital herpes infection, 409-411
- Darkfield microscopy, in syphilis, 546-547
- Delayed hypersensitivity skin testing, in HIV infection, 399-400
- DFA-TP technique, in syphilis, 546-547
- Direct fluorescent antibody test, in syphilis, 546-547
- Direct fluorescent monoclonal antibody stain, in chlamydial infection, 487-489
- Disk-diffusion method, in *Neisseria gonorrhoea* susceptibility testing, 463-464
- DNA hybridization assay, in chlamydial infections, 489-490
 in genital herpes infection, 411-412
 in mycoplasma infections, 514-515
 in papillomavirus infections, 429-436
- Donovanosis (granuloma inguinale), 540-541
- Dot blot technique, in papillomavirus infections, 431-432
- Electron microscopy, in papillomavirus infections, 425-426
- ELISA (enzyme-linked immunosorbent assay), in genital herpes infection, 411
 in HIV infection, 371-372, 376, 380
 in syphilis, 555-556
- Environmental Protection Agency, hazardous waste management and, 574-575, 577-580, 583-585
- Enzyme immunoassay, in chlamydial infections, 489
 in mycoplasma infections, 514, 517
 in syphilis, 555-556
 in vaginal trichomoniasis, 528
- Enzyme-linked immunosorbent assay, in genital herpes infection, 411
 in HIV infection, 371-372, 376, 380
 in syphilis, 555-556
- Epididymitis, mycoplasmas in, 505
- Erythromycin, in gonorrhea, 460-461
- Filter in situ technique, in papillomavirus infections, 432
- Flocculation tests, in syphilis, 548-551
- Fluorescein-labeled antitrichomonal antibody test, in vaginitis, 528
- Fluorescent antibody tests, in chlamydial infections, 487-489
 in genital herpes infection, 411
 in gonorrhea, 457
 in HIV infection, 377
 in mycoplasma infections, 517-518
 in syphilis, 546-547, 551-555
- Fluorescent treponemal antibody absorption double staining test (FTA-ABS DS), in syphilis, 551-555
- Fluorescent treponemal antibody absorption test (FTA-ABS), in syphilis, 551-555
- Gardnerella vaginalis* vaginitis, 528-532, 561
- Genital infections. See *Sexually transmitted diseases*.
- Genital ulcer disease. See *Chancroid*.
- Genital warts. See *Papillomavirus infections, genital*.
- Giemsa stain, in *Chlamydia trachomatis* identification, 486
- Glycoprotein gC test, in genital herpes infection, 414
- Gonochek II test, 454, 456
- GonoGen test, in gonorrhea, 457-458
- Gonorrhea, 445-480
 antigen detection in, 457-458
 antimicrobial susceptibility testing in, 460-470
 colony morphology in, 452-453
 forensic considerations in, 473-474

- incidence of, 445
 - laboratory identification in, 454-459
 - molecular epidemiology in, 470-474
 - nucleic acid probe tests in, 458-459
 - phenotyping in, 473-474
 - presumptive identification in, 452-453
 - rapid biochemical tests in, 454, 456-457
 - specimen for, collection of, 447-450
 - culture of, 451-452
 - Gram stain of, 450-451
 - incubation of, 451
 - toxic factors and, 450
 - transport of, 450
 - test selection in, 459
 - Conozyme test, 457
 - Granuloma inguinale, 540-541
- Haemophilus ducreyi*. See *Chancroid*.
- HATTS (hemagglutination treponemal test for syphilis), 551-552
- Hazardous waste, 573-586
- carcinogenic, 576
 - checklist for, 584
 - chemical, 575-578
 - community and, 583-584
 - corrosive, 575
 - definition of, 575
 - disinfection of, 581-582
 - disposal of, chemical, 577-578
 - infectious, 581-582
 - explosive, 577
 - extraction procedure toxicity of, 576
 - gamma irradiation of, 582
 - gaseous, 583
 - generation of, 573
 - ignitable, 576-577
 - incineration of, 581
 - infectious, 579-582
 - liquid, 578
 - minimization of, 579
 - physical (sharp items), 583
 - radioactive, 582-583
 - regulations on, 574-575
 - steam sterilization of, 581
 - storage of, 577, 580-581
 - toxic, 576
 - transportation of, 577, 581
- Hemagglutination technique, indirect, in mycoplasma infections, 516
- Hemagglutination treponemal test for syphilis, 551-552
- Herpes infections, genital, 405-420
- asymptomatic, 406
 - cell culture techniques for, 409-411
 - clinical features of, 405-407
 - cytologic tests in, 566-567
 - diagnosis of, 406-412
 - DNA detection in, 411-412
 - enzyme-linked immunosorbent assay in, 411
 - microscopy-based tests in, 411
 - neutralization tests in, 412-414
 - protein-specific assays in, 414
 - serologic testing in, 412-416
 - specimen collection in, 408-409
 - specimen transport in, 409
 - symptomatic, 405-406
 - type 1 versus type 2, 412-416
 - virus detection in, 409-412
 - Western blot test in, 415-416
- HIV infection. See *Human immunodeficiency virus infection*.
- HNID Panel, in gonorrhoea, 456
- Hospital waste. See *Hazardous waste*.
- HTLV-I, cross-reactivity of, with HIV-1, 386-387
- Human immunodeficiency virus infection, 369-392
- acute, diagnosis of, 385
 - symptoms of, 370
 - antibody tests in, agglutination, 372
 - confirmatory, 372-378
 - cross reactivity in, 386-387
 - false positive, 386
 - functional, 378
 - immunoassays, 376-377
 - immunoglobulin M capture assay, 378
 - indirect immunofluorescent, 377
 - radioimmunoprecipitation, 377-378
 - screening assays, 371-372
 - Western blot, 372-376
 - asymptomatic, 371
 - beta₂-microglobulin assay in, 398
 - cellular immunity alterations in, 394-395
 - clinical course of, 369-371
 - complement system in, 394
 - delayed hypersensitivity skin testing in, 399-400
 - diagnosis of, algorithm for, 382-385
 - humoral immunity alterations in, 393-394
 - immunoglobulin assay in, 398
 - immunologic evaluation in, 393-403
 - in infants, 386
 - in seronegative but infected patients, diagnosis of, 385-386
 - interferon-gamma production in, 399
 - lymphocyte proliferation to soluble antigen test in, 398-399
 - prognosis of, 381-382
 - screening tests for, in low prevalence populations, 382-385
 - seronegative "window" phase of, 370
 - stages of, 381-382
 - versus viral antigen detection, 380
 - versus virus isolation rates, 379
 - T-cell phenotype analysis in, 396-397
 - type 2, 387
 - viral antigen detection in, 380

- Human immunodeficiency virus infection
(*Continued*)
viral nucleic acids detection in, 380–381
virus isolation in, 378–380
with chancroid, 537
- Human papillomavirus infections. *See Papillomavirus infections.*
- Hypersensitivity skin testing, in HIV infection, 399–400
- IDEIA test, in chlamydial infections, 489
- Identicult-Neisseria test, in gonorrhoea, 456
- IFA (indirect immunofluorescent antibody test), in HIV infection, 377
- Immunoassay, in HIV infection diagnosis, 376–377
- Immunoblot (Western blot) test, in HIV infection, 372–376
- Immunoodeficiency. *See also Human immunodeficiency virus infection.*
mycoplasma infections in, 507–508
- Immunofluorescence tests, in chlamydia infections, 565
in genital herpes infection, 411
in syphilis, 551–555
- Immunoglobulin assay, in HIV infection, 398
in syphilis, 548–551
- Immunoglobulin M capture assay, in HIV infection, 378
in syphilis, 556
- Immunologic evaluation, in chlamydial infection, 487–490
in HIV infection, 393–403
- Immunoperoxidase procedure, in genital herpes infection, 411
- Indirect hemagglutination technique, in mycoplasma infections, 516
- Indirect immunofluorescent antibody test, in HIV infection, 377
- Infants. *See Pediatric patients.*
- Infectious waste management, 579–582
- Infertility, mycoplasmas in, 506
- Interferon-gamma, in HIV infection, 395, 399
- Interleukin production, in HIV infection, 395
- Iodine stain, in *Chlamydia trachomatis* identification, 486
- Keratinosis, abnormal, in papillomavirus infections, 426–428, 568
- Klebsiella denitrificans*, identification of, 456
- Koilocytosis, in papillomavirus infections, 426, 428, 567–569
- Lactobacilli, in vaginosis, 529–530
- Lymphocyte assay, in HIV infection, 396–397
- Lymphocyte proliferation to soluble antigen in vitro test, in HIV infection, 398–399
- Mantoux test, in HIV infection, 399
- Medicolegal cases, gonococci phenotyping in, 473–474
- Meningitis, mycoplasmas in, 507
- Meritec-GC reagent, in gonorrhoea, 457
- Metabolism inhibition techniques, in mycoplasma infections, 516–517
- MHA-TP (microhemagglutination assay), in syphilis, 551–552
- Micro Trak test, in chlamydia infections, 565
- Microhemagglutination assay, in syphilis, 551–552
- Microimmunofluorescence, in mycoplasma infections, 517–518
- Minitek test, in gonorrhoea, 454
- Mobiluncus*, in vaginosis, 529–532
- Monoclonal antibodies, in *Neisseria gonorrhoea* phenotyping, 469–470
- Mycoplasma genitalium*, anatomic localization of, 501–503
antigen detection techniques for, 514
culture methods for, 508–514
DNA probes in, 514–515
in genitourinary tract disease, 503–504
serologic procedures for, 515–518
- Mycoplasma hominis*, complement fixation test for, 516
culture methods for, 508–514
enzyme immunoassay in, 517
in diseases of newborn, 507
in extragenital infections, 507–508
in genitourinary tract disease, 503–507
indirect hemagglutination test for, 516
metabolism inhibition techniques for, 516–517
microimmunofluorescence in, 517–518
serology in, 515–518
- Mycoplasma infections, 501–523
anatomical localization of, 501–503
antigen detection tests in, 514
chorioamnionitis and, 506
complement fixation methods in, 516
culture procedures in, 508–514
DNA probes in, 514–515
enzyme immunoassay in, 517
epididymitis, 505
extragenital, 507–508
in immunocompromised hosts, 507–508
in newborn, 507
indirect hemagglutination technique in, 516
infertility and, 506

- low birth weight associations of, 506
 metabolism inhibition techniques in, 516–517
 microimmunofluorescence techniques in, 517–518
 of central nervous system, 507
 of respiratory tract, 507
 pelvic inflammatory disease, 505–506
 postabortion/postpartum fever and, 506–507
 prostatitis, 504
 pyelonephritis, 505
 serology in, 515–518
 specimen collection/handling in, 508–514
 spontaneous abortion and, 506
 systemic, 508
 T-strain of, 501
 urethritis, 503–504
 urinary calculi and, 505
 vaginosis, 529
- Mycoplasma pneumoniae*, antigen detection techniques for, 514
 in genitourinary tract disease, 503
 serology in, 515–516, 518
- Neisseria gonorrhoeae*. See also *Gonorrhea*.
 antigen detection techniques for, 457–458
 antimicrobial resistance of, 460–463, 471–472
 antimicrobial susceptibility testing of, 460–470
 chromosomal resistance of, 460–461, 471–472
 colony morphology of, 452–453
 culture of, 451–452
 diversity of, 470–471
 dual phenotypic characterization of, 470
 Gram stain of, 450–451
 incubation of, 451
 laboratory identification of, 454–459
 molecular epidemiology of, 470–474
 nucleic acid probe tests for, 458–459
 penicillinase-producing, 461, 472
 phenotyping of, 473–474
 plasmid content of, 467
 plasmid-mediated penicillin-resistant, 461
 plasmid-mediated tetracycline-resistant, 465–466, 472–473
 population dynamics of, 473
 presumptive identification of, 452–453
 rapid biochemical testing of, 454, 456–457
 serotyping of, 467, 469–470
 test selection for, 459
 tetracycline-resistant, 461, 463
 toxic factors and, 450
- Neisseria-Kwik* test, in gonorrhea, 454
Neisseria lactamica, identification of, 453–459
- Neisseria meningitidis*, identification of, 453–459
Neisseria-Stat test, in gonorrhea, 454
 Neoplasia, cervical, papillomavirus and, 423
 Neurosyphilis, tests for, 555–556
 Northern blot test, in papillomavirus infections, 431
 Nuclear Regulatory Commission, radioactive waste disposal and, 582
 Nucleic acid probe tests, in gonorrhea, 458–459
- ORTHOprobe test, in gonorrhea, 458–459
- Pap smear, in candidal infections, 563
 in chlamydia infections, 563–565
 in *Chlamydia trachomatis* identification, 486
 in *Gardnerella vaginalis* infections, 561
 in herpes infections, 566–567
 in papillomavirus infections, 426, 567–569
 in trichomoniasis, 561–563
 in vaginitis/vaginosis, 528, 561–563
 normal vaginal bacterial flora in, 559
- Papillomavirus infections, genital, 421–444
 antigen detection in, 429
 asymptomatic, 424–425
 clinical features of, 424–425
 cytology in, 426, 567–569
 DNA hybridization tests in, 429–436
 electron microscopy in, 425–426
 epidemiology of, 423–424
 histologic tests in, 426–429
 neoplasia and, 423
 serology in, 436–437
 virology of, 421–422
- Pediatric patients, HIV infection in, 386
 mycoplasma infections and, 506–507
- Pelvic inflammatory disease, mycoplasmas in, 505–506
- Penicillin, in gonorrhea, 460–461
- Peptostreptococcus*, in vaginosis, 529–532
- Perinuclear halo, in papillomavirus infections, 568–569
- Peroxidase test, in gonorrhea, 458
- Phadebact Monoclonal GC OMNI reagent, in gonorrhea, 457–458
- Phagocytosis, in HIV infection, 394–395
- Polymerase chain reaction technique, in HIV infections, 380–381
 in papillomavirus infections, 435–436
- Postpartum fever, mycoplasma infections and, 506–507
- Proline aminopeptidase test, in vaginosis, 530
- Prostatitis, mycoplasmas in, 504

- Protein-specific assay, in genital herpes infection, 414
- Pyelonephritis, mycoplasmas in, 505
- Quadferm test, in gonorrhea, 454
- Radioactive waste management, 582-583
- Radioimmunoprecipitation antibody test, in HIV infection, 377-378
- Rapid biochemical tests, in gonorrhea, 454-457
- Rapid N/H test, in gonorrhea, 456
- Rapid plasma reagin test, in syphilis, 548-550
- Reagin screen test, in syphilis, 548-550
- Recombinant DNA technology, in HIV infection diagnosis, 376-377
- Regulations, on hazardous waste management, 574-575
- Respiratory disease, mycoplasmas in, 507
- Reverse blot test, in papillomavirus infections, 431
- RIM-N test, in gonorrhea, 454
- RIPA (radioimmunoprecipitation antibody) test, in HIV infection, 377-378
- RPR (rapid plasma reagin) test, in syphilis, 548-550
- RST (regain screen test), in syphilis, 548-550
- Septicemia, mycoplasmas in, 508
- Serology, in chlamydial infections, 494
in mycoplasma infections, 515-518
in syphilis, 547-548
- Serotyping, of *Neisseria gonorrhoea*, 467, 469-470
- Sexually transmitted diseases. See also *Gonorrhoea*; *Human immunodeficiency virus infection*.
chancroid, 535-540
chlamydial, 481-500
cytopathology of, 559-572
granuloma inguinale, 540-541
herpes infections, 405-420
mycoplasma, 501-523
papillomavirus infections, 421-444
syphilis, 545-557
vaginitis/vaginosis, 525-533
- Skin testing, in HIV infection, 399-400
- Soft chancre. See *Chancroid*.
- Southern blot test, in papillomavirus infections, 430-431
- Spectinomycin, in gonorrhea, 460-461
- Syphilis, 545-557
card tests in, 550-551
congenital, tests for, 555-556
darkfield technique in, 546-547
DFA-TP technique in, 547
direct microscopic examination in, 545-547
enzyme immunoassay in, 555-556
fluorescent treponemal antibody absorption double staining test, 551-555
fluorescent treponemal antibody absorption test in, 551-555
hemagglutination treponemal test in, 551-552
microhemagglutination assay in, 551-552
neuro-, tests for, 555-556
nontreponemal tests in, 548-551
rapid plasma reagin test in, 548-551
regain screen test in, 548-551
serologic tests in, 547-548
toluidine red unheated serum test (TRUST) in, 548-551
treponemal tests in, 551-555
unheated serum reagin test in, 548-551
VDRL slide test in, 548-551
- T-cell phenotype analysis, in HIV infection, 396-397
- Tetracycline, in gonorrhea, 460-461, 463, 465-466, 472-473
- Tissue in situ hybridization, in papillomavirus infections, 432-434
- Toluidine red unheated serum test, in syphilis, 548-550
- Torulopsis glabrata*, in vaginitis, 526
- Transplantation, mycoplasma infections after, 508
- Treponema*. See *Syphilis*.
- Treponemal tests, in syphilis, 551-555
- Trichomonas vaginalis*, in vaginitis, 526-528, 561-563
- TRUST (toluidine red unheated serum test), in syphilis, 548-550
- Ulcer, genital. See *Chancroid*; *Herpes infections, genital*.
- Ulcus molle. See *Chancroid*.
- Unheated serum reagin test, in syphilis, 548-550
- Ureaplasma urealyticum*, anatomic localization of, 501
enzyme immunoassay tests for, 517
in diseases of newborn, 507
in extragenital infections, 507-508
in genitourinary tract disease, 503-507
metabolism inhibition tests for, 516-517
- Urethritis, mycoplasmas in, 503-504

- Urinary calculi, mycoplasmas in, 505
- USR (unheated serum reagin) test, in syphilis, 548-550
- Vagina, normal bacterial flora of, 559
- Vaginitis, 525-528
 cytologic tests in, 561-563
 nonspecific (vaginosis), 528-532, 561
- Vaginosis, 528-532, 561
- VDRL slide, in syphilis, 548-550
- Venereal Disease Research Laboratory slide, in syphilis, 548-550
- Viral testing. See specific virus.
- Virus isolation techniques, in HIV infection, 378-380
- Vitek *Neisseria-Haemophilus* identification card, in gonorrhoea, 456
- Warts, genital. See *Papillomavirus infections, genital*.
- Waste, hazardous. See *Hazardous waste*.
- Western blot test, in genital herpes infection, 415-416
 in HIV infection, 372-376
 in low prevalence populations, 383
- Yeast infections, vaginal, 525-526, 563